Tuberculosis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Tuberculosis - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Tuberculosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Tuberculosis: Overview
Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Tuberculosis is curable and preventable. TB is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. About one-quarter of the world's population has a TB infection, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit it. People infected with TB bacteria have a 5–10% lifetime risk of falling ill with TB. Those with compromised immune systems, such as people living with HIV, malnutrition or diabetes, or people who use tobacco, have a higher risk of falling ill.
'Tuberculosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tuberculosis pipeline landscape is provided which includes the disease overview and Tuberculosis treatment guidelines. The assessment part of the report embraces, in depth Tuberculosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tuberculosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Tuberculosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tuberculosis Emerging Drugs
Further product details are provided in the report..
Tuberculosis: Therapeutic Assessment
This segment of the report provides insights about the different Tuberculosis drugs segregated based on following parameters that define the scope of the report, such as:
Tuberculosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tuberculosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tuberculosis drugs.
Tuberculosis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Tuberculosis - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Tuberculosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Tuberculosis: Overview
Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Tuberculosis is curable and preventable. TB is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. About one-quarter of the world's population has a TB infection, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit it. People infected with TB bacteria have a 5–10% lifetime risk of falling ill with TB. Those with compromised immune systems, such as people living with HIV, malnutrition or diabetes, or people who use tobacco, have a higher risk of falling ill.
'Tuberculosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tuberculosis pipeline landscape is provided which includes the disease overview and Tuberculosis treatment guidelines. The assessment part of the report embraces, in depth Tuberculosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tuberculosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Tuberculosis R&D. The therapies under development are focused on novel approaches to treat/improve Tuberculosis.
This segment of the Tuberculosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tuberculosis Emerging Drugs
- Telacebec (Q203): Qurient Co
- VPM1002: Serum Institute of India
Further product details are provided in the report..
Tuberculosis: Therapeutic Assessment
This segment of the report provides insights about the different Tuberculosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Tuberculosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Tuberculosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tuberculosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tuberculosis drugs.
Tuberculosis Report Insights
- Tuberculosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Tuberculosis drugs?
- How many Tuberculosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tuberculosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tuberculosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Tuberculosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Qurient Co
- Kadmon Gene Therapy Holdings
- Catabasis Pharmaceuticals
- Sequella
- Archivel Farma
- AJ Vaccines
- Sanofi Pasteur
- Aeras
- Immune Network
- Crucell
- Silence Therapeutics
- Biofabri
- GlaxoSmithKline
- NEARMEDIC
- Otsuka Pharmaceutical
- LegoChem Biosciences
- Spero Therapeutics
- Tianjin CanSino Biotechnology
- AnHui Longcom Biologic Pharmacy
- Shanghai Jiatan Pharmatech
- GC Pharma
- Telacebec (Q203)
- VPM1002
- CAT 5571
- Sutezolid
- TBI 223
- RUT Ag85B-ESAT-6-IC31
- AERAS-404
- AERAS-456
- V-7 Immunitor
- AERAS-402/Crucell Ad35
- IMM 201
- MTBVAC
- GSK 692342
- GSK 3036656
- PBTZ-169
- TBA 7371
- OPC 167832
- Delpazolid
- MVA 85A
- SPR 720
- Ad5 Ag85A
- ID 93
- SQ 109
- AEC / BC02
- WX-081
- GC 3107A
- TBA-7371
- TBAJ-876
- TBI-223
Introduction
Executive Summary
Tuberculosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Tuberculosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Tuberculosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Tuberculosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
VPM1002: Serum Institute of India
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Telacebec (Q203): Qurient Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
CAT 5571: Catabasis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Tuberculosis Key Companies
Tuberculosis Key Products
Tuberculosis- Unmet Needs
Tuberculosis- Market Drivers and Barriers
Tuberculosis- Future Perspectives and Conclusion
Tuberculosis Analyst Views
Tuberculosis Key Companies
Appendix
Executive Summary
Tuberculosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Tuberculosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Tuberculosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Tuberculosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
VPM1002: Serum Institute of India
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Telacebec (Q203): Qurient Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
CAT 5571: Catabasis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Tuberculosis Key Companies
Tuberculosis Key Products
Tuberculosis- Unmet Needs
Tuberculosis- Market Drivers and Barriers
Tuberculosis- Future Perspectives and Conclusion
Tuberculosis Analyst Views
Tuberculosis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Tuberculosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Tuberculosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Tuberculosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Tuberculosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
